

March 2, 2015



## Tonix Pharmaceuticals to Present at the 8th Annual European Life Sciences CEO Forum

NEW YORK, March 2, 2015 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) will present at the 8<sup>th</sup> Annual European Life Sciences CEO Forum & Exhibition in Zurich, Switzerland. Seth Lederman, M.D., Tonix's president and chief executive officer, will deliver a corporate overview on Tuesday, March 3<sup>rd</sup> at 2:30 p.m. local time. Earlier that day, Dr. Lederman will participate as a speaker at a Neuroscience Panel at the conference, to be held at 12:00 p.m. local time.

Following the session, a recording of the corporate presentation may be accessed in the Events tab of the Investor Relations page of Tonix's website at [www.tonixpharma.com](http://www.tonixpharma.com). The recording will be archived for 60 days.

Tonix will also be available for one-on-one meetings at the conference.

### About Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals is a clinical-stage pharmaceutical company dedicated to the development of novel medicines for common yet challenging disorders of the central nervous system, including fibromyalgia, post-traumatic stress disorder (PTSD), and episodic tension-type headache. These disorders are characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and significant economic burden. Tonix's TNX-102 SL is in development as a first-line treatment for fibromyalgia and for PTSD. A Phase 2 study in PTSD has recently begun, and Tonix will initiate a Phase 3 program in fibromyalgia in the second quarter of 2015. A Phase 2 trial of TNX-201 for episodic tension-type headache will also begin in the second quarter of 2015. To learn more, please visit [www.tonixpharma.com](http://www.tonixpharma.com).

### Cautionary Note on Forward-Looking Statements

*Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate" and "intend," among others. These forward-looking statements are based on Tonix's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts*

*and dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K filed with the SEC on February 27, 2015 and future periodic reports filed with the Securities and Exchange Commission. All of the Company's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date hereof.*

CONTACT: For additional information contact:

Tonix Pharmaceuticals Holding Corp.  
Leland Gershell  
Chief Financial Officer  
(212) 980-9155 x104  
leland.gershell@tonixpharma.com

Martini Communications  
Amy Martini (investors)  
amartini@martinicomunications.com

Dian Griesel Int'l.  
Susan Forman/Laura Radocaj (media)  
(212) 825-3210  
sforman@dgicomm.com  
lradocaj@dgicomm.com

Source: Tonix Pharmaceuticals Holding Corp.